NCT00170677View on ClinicalTrials.gov

Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

194

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
Ovarian Cancer
Interventions
DRUG

Topotecan

Topotecan 4,0 mg/m² administered in day 1, 8 und 15 as i.v. infusion for 30 minutes. A cycle lasts 28 days.

DRUG

Topotecan

Topotecan 1,25 mg/m²/day, day 1-5 as i.v. infusion of 30 minutes. Repeat after 21 day.

Trial Locations (1)

13533

Charité Campus Virchow-Klinikum, Berlin

All Listed Sponsors
lead

North Eastern German Society of Gynaecological Oncology

OTHER

NCT00170677 - Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian Cancer | Biotech Hunter | Biotech Hunter